The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders.
about
F15063, a potential antipsychotic with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. I. In vitro receptor affinity and efficacy profileThe tetrahydroisoquinoline derivative SB269,652 is an allosteric antagonist at dopamine D3 and D2 receptorsHeritable strain differences in sensitivity to the startle gating-disruptive effects of D2 but not D3 receptor stimulation.Occupancy of dopamine D₂ and D₃ and serotonin 5-HT₁A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomographyHeteromerization of G protein-coupled receptors: relevance to neurological disorders and neurotherapeutics.Integrated signaling in heterodimers and receptor mosaics of different types of GPCRs of the forebrain: relevance for schizophreniaIdentification of dopamine D1-D3 receptor heteromers. Indications for a role of synergistic D1-D3 receptor interactions in the striatumWhat can rodent models tell us about apathy and associated neuropsychiatric symptoms in Parkinson's disease?The role of dopamine and dopaminergic pathways in dystonia: insights from neuroimagingThe NMDA receptor complex: a multifunctional machine at the glutamatergic synapseRecent methods for measuring dopamine D3 receptor occupancy in vivo: importance for drug developmentPharmacological actions of NGB 2904, a selective dopamine D3 receptor antagonist, in animal models of drug addictionThe selective dopamine D3 receptor antagonists SB-277011A and NGB 2904 and the putative partial D3 receptor agonist BP-897 attenuate methamphetamine-enhanced brain stimulation reward in ratsStereochemical and neuroanatomical selectivity of pramipexole effects on sensorimotor gating in ratsRecent advances in methamphetamine neurotoxicity mechanisms and its molecular pathophysiologyThe neurobiology of dopamine receptors: evolution from the dual concept to heterodimer complexesHomology modeling of dopamine D2 and D3 receptors: molecular dynamics refinement and docking evaluationThe Impact of Selective Dopamine D2, D3 and D4 Ligands on the Rat Gambling TaskIn Vitro and In Vivo Characterization of the Alkaloid NuciferineBeyond small-molecule SAR: using the dopamine D3 receptor crystal structure to guide drug designPsychosis in Parkinson's Disease: Epidemiology, Pathophysiology, and Management.A new nosology of psychosis and the pharmacological basis of affective and negative symptom dimensions in schizophrenia.Selective overexpression of dopamine D3 receptors in the striatum disrupts motivation but not cognition.Kappa-opioid receptor signaling in the striatum as a potential modulator of dopamine transmission in cocaine dependenceUsing prepulse inhibition to detect functional D3 receptor antagonism: effects of WC10 and WC44Midbrain dopamine receptor availability is inversely associated with novelty-seeking traits in humansLoss of dopaminergic nigrostriatal neurons accounts for the motivational and affective deficits in Parkinson's disease.Dopamine agonist increases risk taking but blunts reward-related brain activity.A series of 18F-labelled pyridinylphenyl amides as subtype-selective radioligands for the dopamine D3 receptor.Acute D3 Antagonist GSK598809 Selectively Enhances Neural Response During Monetary Reward Anticipation in Drug and Alcohol Dependence.Dopamine D3 and 5-HT1B receptor dysregulation as a result of psychostimulant intake and forced abstinence: Implications for medications development.Implication of dopamine D3 receptor activation in the reversion of Parkinson's disease-related motivational deficits.Characterization of the dopamine receptor system in adult rhesus monkeys exposed to cocaine throughout gestation.A functional fast scan cyclic voltammetry assay to characterize dopamine D2 and D3 autoreceptors in the mouse striatum.Design, synthesis, and structure-activity relationship studies of a series of [4-(4-carboxamidobutyl)]-1-arylpiperazines: insights into structural features contributing to dopamine D3 versus D2 receptor subtype selectivity.Blockade of dopamine D₃ but not D₂ receptors reverses the novel object discrimination impairment produced by post-weaning social isolation: implications for schizophrenia and its treatment.Regulation of dopamine D3 receptors by protein-protein interactionsLevo-tetrahydropalmatine inhibits cocaine's rewarding effects: experiments with self-administration and brain-stimulation reward in rats.Integration of animal behaviors under stresses with different time courses.Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapy.
P2860
Q24564964-3EFE53E5-E2A2-4372-82F2-9A0E8F895E83Q24605967-5D92C210-AD9C-4A02-866D-A77B6F991045Q24612495-3D695CC2-05D0-4615-9D72-3F1080DBA5F7Q24630426-8821AA0B-625F-4CC0-BC6B-CAFCC3DEC54CQ24630645-A42596C5-9C30-48BC-956B-10758D0D95B1Q24632803-5C71B15D-A71C-416D-8285-78787BC0798AQ24651562-4C12D7B8-FC65-46BD-AE7B-E4B3461C4AD0Q26767268-FA440751-BE12-459C-9BD5-1BD9915D5F6EQ26865047-988F66D7-D52A-4255-A79F-5639865C9471Q26992363-A67D5A74-607C-4799-9BFF-BC38356F860FQ27014737-15FD3963-D53F-4A91-88E2-94F8A20452E2Q28236375-5CF22A61-3587-40EF-883A-EAB57B1A9BE4Q28256384-43114D97-A740-4EA2-A34F-7DDED063B3E7Q28256971-6DB1B525-D2F3-44C9-9FC3-CB1009333AA6Q28260273-D70E9163-A502-49A4-92E0-542EBC6EC334Q28289714-22024C76-3C6E-496D-A11F-A70584250ABDQ28483632-3640BCA5-5933-465D-8670-AA2D6277CAEFQ28547805-FE0FA4C2-6287-4A47-8EA5-315E99F8BA5AQ28550683-37797B13-1347-4164-8B42-8935BE80831AQ28828620-366F2872-0D35-4C72-AEFD-A569535E92EDQ30249553-DDE982D3-D939-4A8A-A19F-80427006FBAFQ30423651-A3F4E168-CADB-4F0D-939A-442639B86864Q30423688-B5EFD106-9512-43DA-BE2E-846E85BF0DF6Q30453617-05D04009-DE2E-4E54-B5A4-D7D8CE50E644Q30480298-18A2D801-73E6-43C9-97AE-94E897390C55Q30490410-44F7586A-9591-4E63-B786-E5274244390EQ30829115-74A68502-CFFB-4003-AA4C-EF50C606199AQ33346213-BA83CAE0-BAEE-434A-8A71-61F748EAEDACQ33560926-DA3E6DAD-0379-478E-944F-ED09260AB4ABQ33652844-BE337E73-3FA0-49FA-9346-AC36F85891C9Q33697312-C830A50E-865B-4396-AB64-A9407DDB64B0Q33840503-E5A2DCB5-828D-4761-AA6B-735653177E22Q33884637-6C4E1B38-C98F-4A91-BE3E-39A0E8F63470Q33921257-B305C4BD-3DC3-49B8-BA9B-129077AFC286Q34104379-943D44BD-339D-41D5-A030-CDD035BDAD75Q34171445-12483862-A86A-4A01-89B3-E14F4D6FA8BBQ34193136-7AD753FE-465A-40EA-92F9-6024F519930CQ34247763-B338942F-7B32-48FB-9094-380A3ACB342DQ34319489-1EF5BAE2-30A5-44C7-AC96-2B981D17ABA0Q34325164-33D9E853-9653-4694-939E-2C9EABCC04C1
P2860
The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
The dopamine D3 receptor: a th ...... of neuropsychiatric disorders.
@ast
The dopamine D3 receptor: a th ...... of neuropsychiatric disorders.
@en
type
label
The dopamine D3 receptor: a th ...... of neuropsychiatric disorders.
@ast
The dopamine D3 receptor: a th ...... of neuropsychiatric disorders.
@en
prefLabel
The dopamine D3 receptor: a th ...... of neuropsychiatric disorders.
@ast
The dopamine D3 receptor: a th ...... of neuropsychiatric disorders.
@en
P2093
P1476
The dopamine D3 receptor: a th ...... of neuropsychiatric disorders.
@en
P2093
Sokoloff P
P356
10.2174/187152706784111551
P577
2006-02-01T00:00:00Z